Seaport Therapeutics (SPTX) just entered a long list of Russell indexes, including the Russell 2000 and Russell 3000. This shift can influence how index funds and small cap mandates treat the stock.
Recent trading tells a different story. Seaport Therapeutics has seen its share price fall 18.3% over the past month and 9.6% over the past 90 days, while the year-to-date share price return is only down 1%, so recent momentum has clearly cooled despite the index additions and the latest close at $19.64.
Scan how Seaport Therapeutics compares with other potential small cap rebound stories by reviewing the hand-picked 32 high quality undervalued stocks that have already passed strict fundamental filters.
Index inclusion has pulled Seaport Therapeutics onto more screens just as the share price has slipped. At about $19.64, does the balance of risk and potential reward still lean toward buyers, or not?
Most Popular Narrative: 47% Undervalued
On the most followed view, Seaport Therapeutics screens as materially undervalued, with a fair value estimate of $37 against a last close of $19.64. The valuation debate is really about whether the pipeline can justify that gap.
The main thing that has to go right is that GlyphAllo and GlyphAgo convert their early pharmacology and tolerability signals into clear, placebo separating efficacy with acceptable safety in major depressive disorder and generalized anxiety disorder, despite regulatory expectations for multiple positive trials.
See why 1 investors see Seaport Therapeutics as 47% undervalued.
Result: Fair Value of $37 (UNDERVALUED)
Still, the Seaport Therapeutics story depends on multiple Phase 2 wins and a cash runway that may require extra funding, which could dilute future earnings per share.
Find out about the key risks to this Seaport Therapeutics narrative.
Another View: Seaport Therapeutics On Book Value
The first narrative paints Seaport Therapeutics as materially undervalued on future earnings. On plain book value though, the picture is less generous. The stock trades at a P/B of 2.5x versus a US Pharmaceuticals industry average of 2.2x, so it screens a bit expensive on that simple yardstick.
Peer comparison muddies it. Against similar companies the same 2.5x ratio looks far lower than the 21.6x peer average, which points to a very different risk and opportunity profile. When one model says cheap and another says rich, which lens do you trust for a pre revenue biotech that still has everything resting on Phase 2 data?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals around Seaport Therapeutics can be confusing, so move quickly from headline narratives to the underlying numbers and form your own view by weighing the 4 important warning signs.
Looking for more investment ideas beyond Seaport Therapeutics?
If Seaport Therapeutics has sharpened your focus on valuation and risk, do not stop at a single ticker. Broaden your opportunity set with curated stock ideas surfaced by the Simply Wall St Screener.
- Target potential mispricings by scanning companies that combine quality and value through the 32 high quality undervalued stocks.
- Prioritize resilience by reviewing the 30 resilient stocks with low risk scores that score well on financial strength and business stability.
- Spot early opportunities by checking the 16 high quality undiscovered gems that already clear strict fundamental hurdles before they land on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com